Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD. In addition, the Company announced that participant dosing is underway in the Phase 2 FORGE clinical trial evaluating apitegromab, an investigational fully human monoclonal antibody designed to inhibit myostatin activation, in people living with FSHD. FSHD is a progressive, hereditary neuromuscular disease characterized by muscle atrophy, weakness, and functional decline.